title: Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
authors: A
authors: A
authors: Damasceno
authors: F
authors: F
authors: von Glehn
authors: A R M
authors: AR
authors: Martinez
authors: A L F
authors: AL
authors: Longhini
authors: L
authors: L
authors: Deus-Silva
authors: C O
authors: CO
authors: Brandão
authors: L M B
authors: LM
authors: Santos
authors: B P
authors: BP
authors: Damasceno
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000078785:Mirtazapine; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000008:administration & dosage; D010951:Plasma Exchange; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D010455:Peptides; D008803:Mianserin; D000068717:Glatiramer Acetate; D000078785:Mirtazapine